Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 396

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part II, Item 5
Chunk 396
---
ITEM 5.    OTHER INFORMATION

95

Table of Contents

Departure of Directors or Certain Officers

Marc Tessier-Lavigne, our co-founder and a Board member, has recently informed us of his intention to step down from the Board effective September 1, 2025 to focus on his increased commitments as CEO and Chairman of Xaira Therapeutics, Inc. The Board extends its gratitude to Marc for his significant contributions to Denali over the past decade. We wish him and Xaira continued success.

Securities Trading Plans of Directors and Executive Officers

No officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the second quarter ended June 30, 2025.

96